Related Experiment Videos
Study of the pharmacokinetics of vancomycin in patients with impaired liver function
H. Harada1, Shinichi Miyagawa, Seiji Kawasaki
1Department of Surgery, Chushinmatsumoto Hospital, 811 Kotobukitoyooka, Matsumoto, Nagano 399-0021, Japan.
Abstract:
Infections caused by methicillin-resistant Staphylococcus aureus pose a serious problem postoperatively. Patients with hepatic dysfunction can be considered to be more susceptible to infection. Since little is known about the effects of the severity of hepatic dysfunction on the pharmacokinetics of vancomycin, we studied the pharmacokinetics of vancomycin in preoperative patients with hepatic dysfunction, after the intravenous infusion of 500 mg. In patients with liver disease and normal renal function, an enhancement of renal clearance caused by a reduction in percent protein binding was canceled out by a reduction in non-renal clearance caused by liver dysfunction, resulting in liver disease having no effect on the total clearance of the drug. In patients with impaired liver and renal functions and/or obstructive jaundice, the unbound fraction of vancomycin increased, whereas the renal excretion of vancomycin was delayed. It should be noted that an excessive increase in blood vancomycin concentration may be brought about even with a conventional dose in patients with hepatic dysfunction.
Insights
Vancomycin pharmacokinetics in patients with hepatic dysfunction showed that liver disease alone did not alter total drug clearance. However, impaired liver and renal function delayed vancomycin excretion, increasing blood concentrations.
Area of Science:
- Pharmacology
- Infectious Diseases
- Hepatology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) infections present significant postoperative challenges.
- Hepatic dysfunction may increase patient susceptibility to infections.
- Limited data exists on how hepatic dysfunction severity impacts vancomycin pharmacokinetics.
Purpose of the Study:
- To investigate the pharmacokinetics of vancomycin in preoperative patients with hepatic dysfunction.
- To assess the influence of varying degrees of liver dysfunction on vancomycin clearance and elimination.
Main Methods:
- Intravenous infusion of 500 mg vancomycin was administered.
- Pharmacokinetic parameters were analyzed in patients with liver disease and normal renal function.
- Pharmacokinetics were also studied in patients with combined hepatic and renal impairment or obstructive jaundice.
Main Results:
- In patients with liver disease and normal renal function, reduced protein binding was offset by decreased non-renal clearance, resulting in no net change in total vancomycin clearance.
- In patients with impaired liver and renal function and/or obstructive jaundice, an increased unbound fraction of vancomycin was observed, alongside delayed renal excretion.
- These changes can lead to excessive vancomycin blood concentrations even with standard dosing.
Conclusions:
- Hepatic dysfunction alone does not significantly alter vancomycin total clearance in patients with normal renal function.
- Coexisting renal impairment or obstructive jaundice in patients with hepatic dysfunction significantly affects vancomycin pharmacokinetics, increasing the risk of toxicity.
- Careful vancomycin dosing and monitoring are crucial in patients with hepatic dysfunction, especially when renal function is also compromised.